Susan Langer

Susan Langer is Chief Business Officer at Paratus Sciences. Previously, Susan was Founding President of Kojin Therapeutics, a Boston-based start-up focused on developing transformative medicines based on its groundbreaking approach to ferroptosis and cell state biology. Prior to joining Kojin, Susan was Head of Corporate Strategy at Biogen. During her seven years at Biogen, Susan led the strategy and execution of more than a dozen corporate transactions as well as company-wide initiatives, including expanding the neuromuscular and rare disease franchises. She also played an integral role in deal evaluation and portfolio planning for various parts of the business, including multiple sclerosis, gene therapy, dementia and neurocognition, ophthalmology and non-malignant hematology. Susan is a director of NextRNA Therapeutics. She received a BA from Cornell University.